BridgeBio Pharma (NASDAQ:BBIO) Director Jennifer Cook Sells 148,589 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Jennifer Cook sold 148,589 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $88.54, for a total value of $13,156,070.06. Following the sale, the director owned 8,383 shares in the company, valued at $742,230.82. The trade was a 94.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Price Performance

BBIO stock traded down $2.81 during mid-day trading on Monday, hitting $83.08. 3,372,446 shares of the stock were exchanged, compared to its average volume of 3,149,090. The business has a fifty day moving average price of $69.76 and a 200 day moving average price of $72.09. BridgeBio Pharma, Inc. has a 12 month low of $42.09 and a 12 month high of $93.42. The stock has a market capitalization of $16.27 billion, a price-to-earnings ratio of -22.21 and a beta of 0.95.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million during the quarter, compared to analysts’ expectations of $178.07 million. The company’s revenue was up 66.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.88) EPS. As a group, equities analysts forecast that BridgeBio Pharma, Inc. will post -2.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Morgan Stanley lifted their price target on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, May 28th. Truist Financial upped their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Citigroup started coverage on shares of BridgeBio Pharma in a report on Tuesday, May 19th. They set a “neutral” rating and a $82.00 target price on the stock. HC Wainwright lifted their target price on shares of BridgeBio Pharma from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. Twenty-one research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.40.

Institutional Trading of BridgeBio Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of BBIO. Janus Henderson Group PLC boosted its stake in shares of BridgeBio Pharma by 19.8% during the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after purchasing an additional 2,178,556 shares during the period. Farallon Capital Management LLC increased its stake in shares of BridgeBio Pharma by 9.8% in the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after buying an additional 806,463 shares during the period. Invesco Ltd. raised its holdings in BridgeBio Pharma by 23.0% during the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after buying an additional 902,648 shares during the last quarter. Geode Capital Management LLC raised its holdings in BridgeBio Pharma by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock valued at $344,689,000 after buying an additional 502,582 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in BridgeBio Pharma by 144.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock valued at $292,862,000 after buying an additional 2,261,181 shares during the period. Institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.